Table 1.

Distribution of study population according to demographic/clinicopathologic characteristics and statin use (N = 236)

Statin usersNonusersP*
n (%)37 (16)199 (84)
Age (y)0.63
    Median (IQR)64 (59-67)63 (58-67)
Type of statin (%)
    Simvastatin34 (92)
    Atorvastatin3 (8)
Statin dose equivalent (%)
    <20 mg simvastatin10 (27)
    20 mg simvastatin14 (38)
    >20 mg simvastatin13 (35)
Inflammation grade (%)0.63
    Grade 08 (22)34 (17)
    Grade 117 (46)108 (54)
    Grade 212 (32)57 (29)
Race
    Caucasian24 (65)99 (50)
    African American13 (35)96 (48)
    Other0 (0)4 (2)
Year of surgery0.01
    Median (IQR)2001 (2001-2003)2000 (1998-2002)
PSA0.53
    Median (IQR), ng/mL8.1 (5.2-13.0)7.6 (5.2-11.1)
BMI (%), kg/m20.35
    <258 (25)60 (35)
    25-29.912 (37)67 (40)
    30-34.911 (34)35 (21)
    ≥351 (3)8 (5)
NSAID use before RP27 (73)114 (57)0.07
Biopsy Gleason sum (%)0.007
    2-617 (46)130 (66)
    711 (30)52 (26)
    8-109 (24)16 (8)
Clinical stage (%)0.75
    cT123 (62)111 (62)
    cT2/cT314 (38)76 (41)
Time interval from biopsy to RP0.38
    Median (IQR), d76 (36-103)55 (36-96)
Pathologic Gleason sum (%)0.10
    2-62 (5)40 (20)
    731 (84)138 (69)
    8-104 (11)21 (11)
Extracapsular extension (%)13 (35)49 (25)0.19
Positive surgical margins (%)27 (73)126 (63)0.26
Seminal vesicle invasion (%)8 (22)28 (14)0.25
Lymph node involvement (%)0.38
    Negative16 (43)81 (41)
    Positive1 (3)1 (0.5)
    Not assessed20 (54)117 (59)
Prostate weight0.12
    Median (IQR), g40 (32-52)36 (29-46)

Abbreviation: IQR, interquartile range.

  • *Using χ2 test unless otherwise specified.

  • Using Wilcoxon-Mann-Whitney test.